Replies to post #7604 on Avid Bioservices Inc (CDMO)

[jazzbeerman]

huh?

re: "but that's precisely what I'm talking about."

I'm talking about one drug as therapy for both viruses.

"Protease inhibitors can treat HCV and HIV. There are several PI's on the market for treating HIV. Both IDIX and VRTX's compounds are eligible candidates as is Bavi."

------------------------------------------------


NM283 as HIV therapy?!
An HCV polymerase inhibitor thrown at HIV?

VX950 as HIV therapy?!
An HCV protease inhibitor thrown at HIV?




that's news to me katie.

Hey- here's an idea- how about the reverse! Let's throw Kaletra at HCV.



j

[Big On Tarvy]

"Eligible Candidates" for treating co-infection

Katie, It comes as big news to me to hear that VRTX plans to treat HIV with the same compound it is currently testing against HCV.

Has VRTX talked about this in PRs or CCs or on its website? I know PPHM has frequently listed HIV as one of the next indicatations they may go after with Bavi, but I haven't heard of a comparable statement from VRTX.

Can you give us more info? Thanks

[mskatiescarletohara]

Jazz and BOT.....clarification.


I am talking about IDIX's and VRTX's ability to treat HCV and the potential that it can be administered to coinfected patients who are on HAART therapy. HCV SOC cannot be given to some coinfected patients due to the HAART regimen they are prescribed since not all HIV drugs can be given concurrently as there are harmful interactions from between the various anti-virals.

VRTX's and IDIX's compounds may interact well with some nukes prescribed in HAART therapy, therefore it can potentially carry an expanded label to treat coinfected patients.

I'm not sold on Bavi treating coinfected individuals as a monotherapy. I'd have to see some animal data to support such a conclusion, did SK mention they were conducting any preclinical work for this indication? The company is giving guidance they want Bavi in combo studies, there must be clinical reasons for this strategy.

katie....